
A law firm known for filing shareholder suits says that data supporting a drug company’s plan for trials of its experimental treatment for Alzheimer’s disease show evidence of manipulation.
Stock in the company, Cassava Biosciences, tumbled yesterday after the FDA posted material from the firm, Labaton Sucharow, and a top research integrity expert tells Retraction Watch he sees near-certain signs of fabrication in the data.
Earlier this week, Labaton Sucharow submitted a “citizen’s petition” to the FDA regarding a regulatory filing from Cassava, and called on the agency to halt trials of Cassava’s drug simulfilam on the grounds that it had:
Continue reading Biotech’s data supporting Alzheimer’s trials under scrutiny